JPM24, Day 3: CRISPR CEO touts global potential of Casgevy; Alkermes enters new phase after busy year
JPM24, Day 3: CRISPR CEO touts global potential of Casgevy; Alkermes enters new phase after busy year esagonowsky Wed, 01/03/2024 - 14:47
JPM24, Day 3: CRISPR CEO touts global potential of Casgevy; Alkermes enters new phase after busy year esagonowsky Wed, 01/03/2024 - 14:47
JPM24, Day 2: BioNTech warns of further COVID vaccine sales decline; Alnylam looks to become 'top-tier' biopharma player esagonowsky Wed, 01/03/2024 - 14:40
JPM24, Day 1: Moderna touts $6.7B in '23 sales; Bluebird has cash on hand to last until early 2025 esagonowsky Wed, 01/03/2024 - 14:36
GSK amends commercial deal with Scynexis as antifungal recall drags into 2024 fkansteiner Wed, 01/03/2024 - 11:17
Nexletol partners Esperion and Daiichi Sankyo patch up milestone dispute with $125M settlement zbecker Wed, 01/03/2024 - 10:54
Novo Nordisk, Eli Lilly's obesity drugs will lead in new drug sales in 2024: Evaluate kdunleavy Wed, 01/03/2024 - 10:44
With trial win for oral thalassemia drug, Agios charts broader path than gene therapy rivals aliu Wed, 01/03/2024 - 10:22
FDA slams trio of Indian drugmakers with Form 483 filings after December inspections jkeenan Wed, 01/03/2024 - 08:54
Regulatory tracker: Menarini's Korserdu becomes UK's first new endocrine cancer fighter in decades fkansteiner Wed, 01/03/2024 - 08:41